Piper Sandler analyst Christopher Raymond maintained a Buy rating on Cogent Biosciences (COGT – Research Report) today and set a price target ...
Bernstein analyst William Pickering maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $310.00.
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback